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Summary  Paranasal  sinus  cancers  are  rare,  aggressive  tumours  that  are  usually  diagnosed  at
an advanced  stage.  They  differ  from  other  upper  aerodigestive  tract  tumours  in  terms  of  risk
factors (wood  dust  exposure)  and  premalignant  lesions  (inverted  papillomas).  The  diagnosis
should be  suspected  in  the  presence  of  unilateral  and  continuous  nasal  sinus  symptoms  or
bone lysis  or  a  heterogeneous  opacity  on  imaging.  The  deﬁnitive  positive  diagnosis  is  based  on
histological  examination.  Staging  must  comprise  face,  brain,  neck  and  chest  CT  as  well  as  face
and brain  MRI.  Tumours  are  stage  T3-T4  in  two-thirds  of  cases  and  are  associated  with  cervical
lymph node  involvement  in  10%  of  squamous  cell  carcinomas  and  4%  of  adenocarcinomas.  These
tumours must  be  managed  in  reference  centres  experienced  in  all  of  the  various  treatment
modalities.  Treatment  decisions  must  be  based  on  a  multidisciplinary  approach  comprising  local,
regional and  national  REFCOR  expertise  (French  rare  head  and  neck  cancer  network).  Optimalsurgery;
Radiotherapy;
IMRT
treatment  is  surgical  resection  with  clear  margins  associated  with  adjuvant  intensity-modulated
radiotherapy  (IMRT).  Although  it  has  been  improved  over  recent  decades,  the  prognosis  remains
poor with  local  recurrences  occurring  in  38%  of  cases  and  a  ﬁve-year  overall  survival  of  about
63%.
© 2013  Published  by  Elsevier  Masson  SAS.
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Paranasal  sinus  cancers  are  rare,  aggressive  tumours.  Due
to  their  rarity,  the  diagnostic  modalities  must  be  effectively
mastered  to  avoid  further  delaying  the  classically  late  diag-
nosis  of  these  tumours.  This  delayed  diagnosis  is  related  to
the  late  onset  of  the  relatively  commonplace  symptoms  that
are  often  neglected  by  the  patient.  The  majority  of  tumours
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http://dx.doi.org/10.1016/j.anorl.2012.07.007re  therefore  diagnosed  at  an  advanced  stage,  requiring
nvasive  and  mutilating  surgery.
The  rarity  of  these  tumours  also  explains  the  limited  sci-
ntiﬁc  rationale  and  the  low  level  of  proof  of  treatment
uidelines  in  this  ﬁeld.  Modiﬁcations  of  the  gold  standard
epresented  by  a  combination  of  surgery  and  radiothe-
apy  have  been  recently  introduced:  endonasal  surgery,
MRT  radiotherapy,  induction  or  concomitant  chemothe-
apy,  complex  reconstructions,  etc.  The  prognosis  of  these
umours  has  been  improved  and  the  functional  results  of
hese  innovative  treatments  are  also  the  subject  of  close
crutiny.
This  article  is  designed  to  present  a  didactic  review  of
he  current  knowledge  concerning  the  diagnosis,  treatment
nd  prognosis  of  paranasal  sinus  cancers.
.
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Figure  1  Nasal  endoscopy:  granulating  tumour  arising  from  the  right  ethmoid  sinus.  The  tumour  may  be  visualized  either  in  the
region of  the  middle  meatus  (left  image)  or  in  the  olfactory  groove  (right  image).
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ode  of  presentation
n  the  vast  majority  of  cases,  these  tumours  are  diagnosed
t  the  stage  of  symptoms.
When  the  tumour  has  only  invaded  the  paranasal
inuses,  symptoms  are  non-speciﬁc:  unilateral  blocked  nose,
ucopurulent  rhinorrhoea,  and  epistaxis.  These  symptoms
re  neglected  for  a  long  time  by  patients,  who  are  usually
hronically  exposed  to  wood  dust  and  who  have  experienced
hese  symptoms  for  very  many  years.  In  a  study  that  we
onducted  on  934  wood  dust  exposed  workers  in  Brittany
etween  2007  and  2009,  25%  of  subjects  reported  blocked
ose,  18%  reported  rhinorrhoea,  18%  reported  sneezing,
.9%  reported  epistaxis  and  7.5%  reported  dysosmia.  How-
ver,  these  symptoms  were  bilateral  or  alternating  in  92.6%
f  cases  (in  press).
The  unilateral  and  continuous  nature  of  these  symp-
oms  must  raise  the  suspicion  of  paranasal  sinus  can-
er.
Extension  beyond  the  sinuses,  in  addition  to  sinus  symp-
oms,  also  causes  neurological  (headache,  anaesthesia  in
he  territory  of  the  trigeminal  nerve),  ophthalmological
exophthalmos,  recurrent  conjunctivitis,  diplopia)  or  dental
ymptoms  (pain  or  mobility  of  maxillary  teeth).
Paranasal  sinus  cancers  are  rarely  diagnosed  or  suspected
efore  the  onset  of  symptoms,  but  may  be  an  incidental
nding  on  imaging  or  histology  or  can  rarely  be  discovered
ystematically  in  the  context  of  early  screening  programmes
n  exposed  occupations.  However,  since  28  February  1995,
rticle  D461-25  of  the  French  Social  Security  Code  has
roposed  ‘‘ENT  examination,  chest  X-ray,  sinus  X-rays,  pos-
ibly  completed  by  ﬁve  or  six  frontal  CT  sections’’  every
 years  for  workers  exposed  to  wood  dust  under  certain
xposure  conditions.  The  French  Société  de  Médecine  de
ravail  (French  Society  of  Occupational  Medicine)  guidelines
ublished  in  2011  and  validated  by  iNCA  (French  Cancer
nstitut)  and  the  HAS  (High  Authority  of  Health)  propose
asal  endoscopy  every  2  years  in  subjects  with  cumulative
xposure  greater  than  12  months  over  a  period  of  more  than
0  years.
O
a
p
alinical  examination
he  nasal  fossae  must  be  examined  with  a bivalve  rhinoscope
r  nasal  speculum  using  a  suction  system  to  eliminate
he  often  abundant  secretions  from  the  nasal  fossae  and
otton  buds  soaked  in  Xylocaine® with  5%  naphazoline.
his  examination  allows  direct  visualization  of  the  tumour,
hich  presents  the  characteristics  of  a  malignant  tumour:
rregular  and  granulating,  contact  bleeding,  painless.  It
an  be  visualized  at  various  levels:  underneath  the  mid-
le  turbinate,  arising  directly  from  the  ethmoid  sinus,
n  the  olfactory  groove  (Fig.  1),  anywhere  in  the  nasal
ossa  as  far  as  the  ﬂoor  or  even  in  the  nostril.  More
arely,  polyps  with  a  benign  appearance  may  mask  the
umour  itself,  therefore  resulting  in  a  false-negative  diag-
osis.
Clinical  examination  then  comprises  the  use  of  a  ﬂexi-
le  or  rigid  0◦ and/or  30◦ optic  nasal  endoscope  in  order
o  visualize  the  tumour  and  try  to  delineate  its  con-
ours.
Examination  of  the  oral  cavity  must  look  for  vaulting  of
he  palate,  soft  palate,  cheek,  superior  gingivolabial  sul-
us,  or  mobility  of  the  maxillary  teeth.  Posterior  rhinoscopy
sing  a mirror  may  visualize  the  posterior  part  of  the
umour  which  protrudes  into  the  nasopharynx.  This  visual
nspection  must  be  systematically  combined  with  endobuc-
al  palpation,  which  is  sometimes  the  only  way  to  induce
uspicious  contact  bleeding  or  reveal  submucosal  indura-
ion  not  detected  by  inspection.  The  rest  of  the  upper
erodigestive  tract  mucosa  must  be  systematically  exam-
ned  looking  for  a  possible  second  tumour,  especially  in
atients  with  associated  alcohol  and  smoking  risk  factors.
toscopic  examination  may  reveal  seromucous  otitis  which,
n  this  context,  is  suggestive  of  auditory  tube  obstruction.
ll  cervical  lymph  node  areas  must  be  palpated  looking  for
ymphadenopathy.
Neurological  examination  must  test  all  cranial  nerves,
articularly  the  three  divisions  of  the  trigeminal  nerve.
phthalmological  examination  looks  for  exophthalmos
nd  determines  whether  or  not  it  is  reducible,  the
resence  of  defective  eye  tracking  or  loss  of  visual
cuity.
Paranasal  sinus  cancer  
Figure  2  CT  scan  of  the  sinuses,  bone  window  setting,  sag-
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Hittal section.  The  arrow  indicates  osteolysis  of  the  roof  of  the
anterior  part  of  the  ethmoid  sinus.
Diagnostic  imaging
When  clinical  examination  demonstrates  the  typical  fea-
tures  of  a  malignant  tumour  and  in  the  absence  of
contraindications,  biopsy  can  be  performed  immediately.  In
this  case,  imaging  is  essentially  performed  for  staging  pur-
poses.
In  the  other  cases,  imaging  can  conﬁrm  the  suspicion  of
malignant  tumour,  ensure  the  absence  of  contraindication
to  biopsy  (intensely  contrast-enhanced  lesion)  and  is  useful
for  staging  (Figs.  2,  3).  The  ﬁrst-line  examination  is  com-
puted  tomography  of  the  sinuses  with  bone  and  soft  tissue
windows  and  contrast  injection.  Examination  must  focus  on
Figure  3  MRI,  gadolinium-enhanced  T2-weighted  sequence,
axial scan.  The  ethmoid  sinus  presents  an  exuberant  heteroge-
neous opacity  extending  onto  the  anterior  wall  of  the  sphenoidal
sinus which  is  lysed.  The  maxillary  sinus  presents  a  homoge-
neous  mucosal  opacity.
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he  sinus  walls  and  contents.  Signs  suggestive  of  malignant
umour  are  osteolysis  of  the  sinus  walls,  unilateral  and/or
eterogeneous  opacity  of  the  nasal  cavity  or  sinus  with  het-
rogeneous  enhancement.  MRI  can  also  suggest  the  diagnosis
n  the  presence  of  a heterogeneous  unilateral  opacity.
ifferential  diagnosis
nilateral  nasal  sinus  polyposis  and  inverted  papilloma  can
resent  the  clinical  features  of  paranasal  sinus  cancer.  How-
ver,  this  diagnosis  must  always  be  conﬁrmed  by  biopsy.
The  presence  of  unilateral  but  homogeneous  opacity  of
he  sinus  with  intact  bony  walls  may  indicate  a  diagnosis
f  Kilian’s  polyp.  The  deﬁnitive  diagnosis  is  based  on  his-
ological  examination.  Opacity  of  the  sinus  associated  with
steolysis  may  correspond  to  mucocele  or  odontogenic  cyst.
n  both  of  these  cases,  the  mass  remains  very  regular  and  is
ften  surrounded  by  a ﬁne  layer  of  bone,  reﬂecting  the  slow
nd  noninvasive  growth  of  the  lesion.
Heterogeneous  unilateral  sinus  opacity  sinus  with  intact
ony  walls  may  correspond  to  a  diagnosis  of  sinus  aspergillo-
is.  Treatment  is  surgical  and  all  operative  specimens  must
e  submitted  to  histological  examination.  The  presence
f  lysis  of  the  bony  walls  may  indicate  ﬁbrous  dyspla-
ia  or  benign  tumours  (ossifying  ﬁbroma,  cemento-ossifying
broma).
istology
nly  biopsy  and  histological  examination  can  provide  the
eﬁnitive  diagnosis.  A  tumour  fragment  must  be  frozen  for
torage  in  a tumour  bank,  when  available.  As  these  tumours
re  rare,  the  slides  must  be  reviewed  when  there  is  any
oubt  about  the  diagnosis  or  in  the  case  of  doubtful  histol-
gy.  The  distribution  of  histological  types  varies  from  one
ountry  to  another  with,  globally,  squamous  cell  carcinoma
ccounting  for  50%  of  all  sinus  tumours,  adenocarcinoma:
2%,  adenoid  cystic  carcinoma:  10%,  non-Hodgkin’s  lym-
homa:  11%,  olfactory  esthesioneuroblastoma:  3%,  sarcoma:
%  and  mucosal  melanoma:  2%  [1]. This  list  is  not  exhaustive
nd  the  WHO  classiﬁcation  comprises  a  very  large  range  of
umours  in  this  site.
A correlation  between  tumour  site  and  histology  is  typ-
cally  observed.  Ethmoid  tumours  are  adenocarcinomas  in
5%  of  cases  and  maxillary  sinus  tumours  are  squamous  cell
arcinomas  in  75%  of  cases.  The  nasal  fossae  are  mainly
he  primary  site  of  squamous  cell  carcinoma,  malignant
elanoma  and  olfactory  esthesioneuroblastoma.
taging  assessment
ssessment  of  a cancer  comprises  a  general  assessment
f  the  patient  and  staging  of  the  tumour.  Assessment  of
he  patient  must  comprise  a  diagnosis  disclosure  consul-
ation,  an  anaesthetic  consultation,  nutritional  assessment
BMI,  serum  albumin),  pain  assessment  (VAS),  evaluation
nd  management  of  risk  factors  (occupational  medicine,
moking  and  alcohol  withdrawal,  when  associated).  Staging
omprises  CT  and  MRI  of  the  facial  bones  and  contrast-
nhanced  CT  of  the  neck  and  chest.
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CT  of  the  facial  bones  (Fig.  2)  is  designed  to  determine
he  limits  of  the  tumour,  identify  zones  of  osteolysis  and  any
natomical  variants  (optic  nerve,  internal  carotid  vessels).
MRI  (Fig.  3)  is  performed  systematically  and  must  com-
rise  at  least  two  T1-weighted  sequences  before  and  after
njection,  a  T2-weighted  sequence  in  at  least  two  different
lanes,  and  a  diffusion  sequence.  MRI  is  able  to  distinguish
ones  of  ﬂuid  retention  from  zones  of  tumour  invasion  (T2-
eighted  and  FLAIR  sequences),  and  can  identify  invasion
f  the  periorbital  fat  (FAT-SAT  and  STIR  sequences)  and
nvasion  of  the  dura  mater  (gadolinium-enhanced  T2  and
1  sequences)  and  cerebral  cortex.  MRI  also  has  a  higher
ensitivity  than  computed  tomography  for  the  diagnosis  of
nvasion  of  the  infratemporal  fossa  and  pterygopalatine
ossa  [2].
The  place  of  PET-CT  (Fig.  4)  has  not  yet  been
learly  deﬁned  and  no  formal  consensus  has  been  reached
oncerning  this  indication.  According  to  the  2003  Standards-
ptions-Recommendations  of  the  Fédération  de  Lutte
ontre  le  Cancer  (French  cancer  centre  federation),  this
xamination  can  be  performed  as  part  of  the  standard  ini-
ial  staging  assessment  (level  of  proof  B2)  [3].  Wild  reported
he  results  of  PET  for  initial  staging  and  restaging  in  a
eries  of  21  patients  with  paranasal  sinus  cancer  [4]. PET
emonstrated  distant  metastases  in  ﬁve  patients,  resulting
n  treatment  modiﬁcation  for  nine  patients.  However,  it
emains  to  be  demonstrated  whether  these  treatment  mod-
ﬁcations  result  in  a  beneﬁt  for  the  patient.
lassiﬁcations
he  ofﬁcial  classiﬁcation  of  paranasal  sinus  tumours  is  the
ICC  TNM  2006  classiﬁcation  [1].  It  essentially  has  a  pro-
nostic  value,  but  also  allows  homogeneous  classiﬁcation,
acilitating  communication  and  publication.
Sixty  seven  percent  of  squamous  cell  carcinomas  of  the
axillary  sinus  are  stage  T3-T4  [5],  while  the  majority  of
denocarcinomas  of  the  ethmoid  sinus  are  stage  T2  (32%)
nd  T4  (40%).  Lymph  node  invasion  is  detected  in  10%  of
quamous  cell  carcinomas  of  the  maxillary  sinus  and  2.4%  of
denocarcinomas  of  the  ethmoid  sinus  [6,7].  Distant  metas-
ases  are  present  in  only  about  2%  of  paranasal  sinus  cancers
t  the  time  of  the  initial  diagnosis  [7].
reatment
reatment  modalities
urgery
echniques  without  skull  base  resection  comprise  all
ransfacial  approaches  [8],  including  lateral  rhinotomy,
ouge-Denker  rhinotomy,  and  the  buccal  vestibular  or
‘degloving’’  approach.
Skull  base  resection  can  be  performed  via  several
pproaches.  The  mixed  approach  combines  a  subfrontal
pproach  with  a  transfacial  approach,  either  lateral  rhino-
omy,  or,  less  commonly,  a  bilateral  sublabial  approach
degloving)  [9]  or  a  transmaxillary  approach  [10]. Pure  trans-
ranial  approaches  (bicoronal  incision)  have  the  advantage
f  avoiding  a  facial  incision  [11].  Finally,  skull  base  resection
an  be  performed  via  a  purely  transfacial  approach,  which
T
T
tF.  Jégoux  et  al.
as  the  advantage  of  allowing  management  of  unexpected
ntraoperative  ﬁndings  [12,13].
For  a  long  time,  endonasal  surgery  was  reserved  for  small
umours,  but  improvement  of  instrumentation  and  neu-
onavigation  now  allows  resection  of  much  larger  tumours
Fig.  5) [14—18].  The  European  Rhinologic  Society  held
 meeting  in  2010  to  more  clearly  deﬁne  and  classify
he  indications  and  the  surgical  technique  itself  [1].  It
ecommended  that  endonasal  surgery  be  reserved  to  teams
lready  experienced  in  conventional  skull  base  surgery  and
ndonasal  surgery  in  general,  and  that  a  learning  curve  be
bserved  by  starting  with  small  tumours  without  invasion
eyond  the  sinus.
adiotherapy  [19—26]
he  recommended  dose  for  exclusive  radiotherapy  or  post-
perative  macroscopic  residual  tumours  is  70  Gy  for  the
umour  and  metastatic  lymph  nodes.  A  dose  of  50  to  66  Gy
s  delivered  to  zones  at  high  risk  of  microscopic  extension.
For  adjuvant  radiotherapy,  the  dose  prescribed  to  the
umour  site  is  50  to  66  Gy,  with  a  dose  of  at  least  60  Gy  to
esidual  tumour  and  lymph  nodes  with  capsular  effraction.
ractionation  consists  of  ﬁve  fractions  of  1.8-2  Gy  per  week.
The  tumour  target  volume  together  with  its  microscopic
xtensions  only  comprises  all  of  the  affected  sinus  when
umour  extension  is  strictly  conﬁned  to  the  sinus.  The  target
olume  is  extended  to  adjacent  structures  in  the  presence
f  documented  effraction,  such  as  the  orbit  in  the  case  of
eriosteal  effraction  of  the  orbital  wall,  the  nasal  fossa,  an
djacent  sinus  or  the  pterygomaxillary  fossa.
Radiotherapy  is  made  complex  by  the  proximity  of  target
olumes  and  vital  structures  (eye,  brain  and  hypothalamo-
ituitary  axis).  Three  dimensional  conformal  radiotherapy,
ased  on  the  initial  CT  treatment  planning,  has  reduced
he  treated  volumes  and  consequently  the  dose  delivered
o  vital  organs.  Conformal  intensity-modulated  radiothe-
apy  (IMRT)  allows  modulation  of  the  intensity  of  irradiation
eams  during  the  treatment  session.  IMRT  can  be  used  to
rradiate  concave  tumours,  while  sparing  adjacent  healthy
issues.  IMRT  allows  the  use  of  simultaneous  integrated
oost  (SIB),  simultaneous  modulated  accelerated  radiation
herapy  (SMART)  and  dose  escalation  (new  dose  painting
oncept)  techniques.
hemotherapy
he  protocols  most  widely  used  at  the  present  time  com-
rise  concomitant  administration  of  cisplatin  at  a  dose
f  100  mg/m2 on  D1,  D22  and  D43.  The  combination  of
latinum  +  5FU  +  cetuximab  (extreme  protocol)  can  be  used
s  ﬁrst-line  treatment  for  inoperable  recurrent  and/or
etastatic  tumours.
Complications  are  haematological  (anaemia,  thrombocy-
openia),  cardiac,  neurological  (neuropathies),  nephrologi-
al,  cutaneous  (particularly  with  cetuximab),  otological  and
astrointestinal  (mucositis,  diarrhoea).
ational  bases  [6,7,25,27,28]reatment  of  the  tumour
he  combination  of  surgery  and  radiotherapy  is  more  effec-
ive  than  radiotherapy  alone.  The  sequence  of  surgery
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[Figure  4  PET-CT,  axial  scan.  PET  demonstrates  signiﬁcant  upt
while recurrence  is  not  clearly  visualized  on  contrast-enhanced
followed  by  radiotherapy  allows  better  local  control  than
the  reverse  sequence.  The  prognosis  of  very  large  tumours
is  highly  dependent  on  tumour  resectability.  Surgery  alone
may  be  sufﬁcient  for  stage  T1  tumours  except  in  the  case  of
invaded  margins,  perineural  invasion  or  an  undifferentiated
contingent.
Endonasal  surgery  allows  at  least  identical  survival  for
adenocarcinomas  or  even  better  survival  for  esthesioneuro-
blastomas  with  decreased  morbidity,  but  it  requires  partic-
ular  skills  [1,29,30].
Treatment  of  lymph  nodes  [5—7,31]
The  risk  of  lymph  node  invasion  is  higher  for  squamous  cell
carcinomas  (10%),  esthesioneuroblastomas  and  lymphomas,
in  the  presence  of  invasion  of  the  facial  skin  or  the  maxi-
llary  infrastructure.  Radiotherapy  to  N0  zones  signiﬁcantly
decreases  the  lymph  node  recurrence  rate  in  these  territo-
ries.  The  treatment  of  choice  of  N+  tumours  is  a  combination
of  exenteration  followed  by  adjuvant  radiotherapy.  There  is
i
r
m
w(SUVmax  12)  in  the  right  pterygopalatine  fossa  (lower  images),
left  upper  image)  and  MRI  axial  sections  (right  upper  image).
 correlation  between  lymph  node  recurrence  and  the  risk
f  distant  metastases.
IMRT  has  been  demonstrated  to  reduce  acute  and  late
oxicities  [1,32]  and  improve  quality  of  life  [33].  Its
eneﬁt  on  reduction  of  hyposialia  has  been  demonstrated
n  three  randomized  trials,  but  not  speciﬁcally  concerning
aranasal  sinus  tumours.  The  few  available  retrospective,
on-randomized  series  comprised  a  small  number  of  patients
ith  paranasal  sinus  tumours  treated  by  IMRT  [23—26]  and
emonstrated  improved  survival  and  less  toxicity  compared
o  historical  series  without  IMRT.  3D  conformal  radiotherapy
an  be  used  when  IMRT  is  not  available  (REFCOR  2009).
Only  limited  data  are  available  speciﬁcally  concerning
hemotherapy  for  paranasal  sinus  cancer.  The  studies  by
olero  et  al.  [34],  Roux  et  al.  [35,36]  and  Georges  et  al.
37]  suggested  the  possible  value  of  induction  chemotherapy
n  selected  cases.  Roux  et  al.  [35,36]  reported  a complete
esponse  conﬁrmed  by  histology  on  the  operative  speci-
en  in  14%  of  patients  (11  out  of  76  patients),  none  of
hom  relapsed.  The  actuarial  10-year  survival  remains  100%
332  F.  Jégoux  et  al.
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aigure  5  Neuronavigation.  The  neuronavigation  control  screen
T scan  and  provides  information  on  anatomical  relations  with  
or  these  patients.  However,  the  tumour  stage  of  these
1  complete  responder  patient  was  not  speciﬁed  and  par-
ially  responding  patients  had  a  less  favourable  survival  than
on-responders.  Georges  et  al.  [37]  reported  a  complete
esponse  rate  of  only  6%  in  a  series  of  31  patients.  The  impact
f  chemotherapy  on  overall  survival  has  not  been  clearly
emonstrated,  but  a  complete  response  may  constitute  a
actor  of  good  prognosis.  The  place  of  chemotherapy  has  yet
o  be  deﬁned,  as  the  sample  sizes  of  published  series  are  too
mall  to  demonstrate  a  real  beneﬁt  in  terms  of  survival.
ndications  [6,7,25,29]
n  clinical  practice,  management  therefore  depends  on
atient-related  factors  (operability,  comorbidities,  personal
references),  tumour-related  factors  (TNM,  histology,  site,
esectability),  and  surgical  team-related  factors  (exper-
ise).
Treatment  according  to  tumour  site  are  the  following:
 when  the  tumour  is  resectable,  the  treatment  of  choice
is  a  combination  of  surgery  and  adjuvant  radiotherapy.
Adjuvant  radiotherapy  may  be  unnecessary  in  cases  with
a  good  prognosis:  stage  T1-T2  adenocarcinoma,  stage
T1  squamous  cell  carcinoma,  grade  A  and  B  olfac-
tory  esthesioneuroblastoma  (Kadish  classiﬁcation)  with
negative  resection  margins.  A  combination  of  concomi-
tant  chemotherapy  and  adjuvant  radiotherapy  (optional)
can  be  performed  in  cases  of  squamous  cell  carcinoma
with  positive  resection  margins;
t
•
•vides  the  surgeon  with  real-time  navigation  on  the  preoperative
 structures.
 the  treatment  for  unresectable  tumours  is  radiotherapy
alone  or  a  combination  of  concomitant  radiotherapy  and
chemotherapy  for  squamous  cell  carcinoma.
Below  are  the  cases  of  the  treatment  of  lymph  nodes:
 in  the  case  of  clinical  or  radiological  lymph  node  inva-
sion,  a  modiﬁed  radical  dissection  must  be  followed  by
adjuvant  radiotherapy;
 in  the  absence  of  clinical  or  radiological  lymph  node  inva-
sion,  situations  at  high  risk  of  lymph  node  invasion  must  be
treated  by  cervical  node  irradiation:  squamous  cell  car-
cinoma,  melanoma,  high-grade  esthesioneuroblastoma.  A
wait-and-see  approach  to  lymph  nodes  can  be  proposed
in  other  cases;
 the  decision  taken  in  multidisciplinary  meetings  must  then
be  proposed  and  explained  to  the  patient.  Information
concerning  the  advantages  and  disadvantages  of  the  vari-
ous  treatments  must  be  explained,  ideally  in  the  context
of  another  diagnosis  disclosure  consultation.  The  treat-
ment  plan  is  recorded  in  a  personalized  treatment  plan
given  to  the  patient  with  a  copy  in  the  patient’s  medical
ﬁle.
Curative  treatment  must  be  associated  with  symptomatic
reatment  and  appropriate  supportive  care,  which  requires
 preliminary  assessment  of  the  patient,  also  recorded  in
he  patient’s  medical  ﬁle:
 pain  (VAS:  visual  analogue  scale);
 nutrition  (body  mass  index,  possibly  serum  albumin);
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•  psycho-oncology;
•  geriatric  oncology;
•  social  aspects;
•  aesthetic  aspects.
Palliative  situations  must  take  all  of  these  data  into
account  and  the  intervention  of  a  specialized  structure  in
palliative  cares  is  highly  desirable.
Results
Survival
The  prognosis  is  essentially  determined  by  local  control.  In
the  Gettec  multicentre  study  based  on  418  patients,  Choussy
et  al.  reported  a  local  recurrence  rate  of  38%  and  a  5-year
overall  survival  of  63%.  In  2001,  in  a  meta-analysis  combined
with  a  large  series  of  new  cases,  Dulguerov  reported  a  highly
variable  5-year  survival  rate  as  a  function  of  histological  type
(78%  for  adenocarcinomas,  60%  for  squamous  cell  carcino-
mas),  site  (62%  for  maxillary  sinus,  48%  for  ethmoid  sinus),
and  stage  (91%  for  T1,  49%  for  T4)  [7].
Functional  results
The  majority  of  patients  suffer  from  chronic  crusting  rhini-
tis,  lacrimation,  and  sometimes  sensory  loss  of  the  maxillary
division  of  the  trigeminal  nerve  following  lateral  rhinotomy.
Few  studies  have  reported  the  functional  results,  parti-
cularly  in  terms  of  the  quality  of  life  of  these  patients.  In
our  experience  based  on  31  patients  operated  by  transfa-
cial  anterior  skull  base  resection  between  2005  and  2010,
a  signiﬁcant  impact  on  quality  of  life  was  observed  for
the  fatigue,  pain,  and  dyspnoea  items  of  the  EORTC  QLQ30
questionnaire;  88%  of  facial  heaviness/nasal  respiratory  dis-
comfort  with  the  Rhino-QOL  questionnaire,  and  10%  of
dysexecutive  behavioural  disorders  with  the  DEXT  question-
naire  (Bordigoni  et  al.,  in  press).
Follow-up
In  line  with  the  SFORL  2008  guidelines,  follow-up  must  con-
cern  the  disease  and  the  patient:  clinical  examination  every
two  months  for  the  ﬁrst  year,  every  three  months  for  the
second  year,  then  every  six  months  for  life;  MRI  every  3
months  after  treatment,  then  in  the  light  of  clinical  exa-
mination;  chest  x-ray  at  6  months  then  once  a  year.  Annual
dental,  ophthalmological  and  pituitary  function  follow-up  is
also  essential.
Compensation
In  2008,  70  primary  cancers  of  the  ethmoid  and  facial
sinuses  and  10  nasal  fossa  cancers  were  recognized
as  occupational  diseases.  This  ﬁgure  includes  cases
recognized  in  the  context  of  Occupational  Disease  tables
(paragraph  2  of  Article  l  461-1  of  the  French  Social
Security  Code)  (data  derived  from  the  Eurogip  2010
report.  Source:  CNAMTS,  Occupational  risks  department;
http://www.eurogip.fr/docs/RA  EUROGIP2010  F.pdf).
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This  low  occupational  cancer  compensation  rate  can  be
ssentially  explained  by  the  absence  of  declaration,  directly
elated  to  the  doctor’s  lack  of  awareness  of  work-related
ealth  problems.  Furthermore,  because  of  the  long  latency
etween  exposure  and  diagnosis  of  cancer  (generally  at  least
0  years  and  sometimes  more  than  40  years),  work-related
ancers  are  often  diagnosed  a  long  time  after  the  subject
as  left  the  job  concerned.  Declaration  as  a  chronic  dis-
ase  is  often  wrongly  considered  to  be  more  important  than
eclaration  as  an  occupational  disease.
The  individual  advantage  of  declaration  as  an  occupa-
ional  disease  is  better  compensation  and  job  protection
French  law  dated  7  January  1981).  The  advantage  for  the
ommunity  is  to  ensure  funding  by  the  employer-funded
‘Work  accidents  -  Occupational  diseases’’  branch  of  Social
ecurity,  and  to  improve  protection  measures.
Table  47  of  the  General  Social  Security  Scheme  and
able  36  of  the  Agricultural  Social  Security  Scheme  deﬁne
he  conditions  of  recognition  of  wood  dust-  and  nickel-
elated  occupational  diseases:  histology  (carcinoma),  site
sinuses  and  nasal  fossae),  causal  factor  (wood  dust  or
ickel),  minimal  exposure  time  (5  years),  time  to  manage-
ent  (40  years).  In  the  other  cases,  an  application  must
e  submitted  to  the  Commission  Régionale  de  Reconnais-
ance  des  Maladies  Professionnelles  (Regional  occupational
isease  recognition  commission)  (CRRMP,  Law  93-121  dated
7/01/1993).
rogress
 signiﬁcant  survival  gain  has  been  observed  over  recent
ecades.  This  survival  gain  has  been  observed  for  the
urgery  +  radiotherapy  combination,  but  not  with  other
reatment  modalities,  for  cancers  of  the  maxillary  sinus  and
thmoid  sinus,  but  not  for  cancers  of  the  nasal  fossae  and
quamous  cell  carcinomas.  A  less  signiﬁcant  survival  gain  has
een  observed  for  adenocarcinomas  [7,38].
In  the  ﬁeld  of  diagnostic  imaging,  MRI,  but  also  metabolic
maging  (PET/CT),  have  allowed  more  accurate  delineation
f  these  tumours  in  which  the  prognosis  is  related  to  local
ontrol.  Among  other  things,  this  has  allowed  the  develop-
ent  of  neuronavigation  and  images  fusion  techniques  for
adiotherapy.
Progress  in  surgery  has  concerned  skull  base  recon-
truction  techniques,  decreased  morbidity  of  surgical
pproaches,  and  especially  endoscopic  or  endonasal  surgery
uided  by  neuronavigation,  by  single  or  double  teams  (4-
and  endoscopic  surgery).
In  the  ﬁeld  of  radiotherapy,  arc  therapy  techniques  (simi-
ar  to  tomotherapy,  but  using  a  standard  linear  accelera-
or)  will  probably  rapidly  allow  the  widespread  use  of  IMRT
echniques.  The  Cyberknife® (robotic  radiosurgery  system),
llowing  irradiation  with  millimetric  precision,  is  also  being
eveloped  in  many  centres.
onclusionaranasal  sinus  cancers  are  rare,  but  aggressive  tumours.
elayed  management  is  partly  related  to  neglect  of  symp-
oms  by  patients  but  also  underdiagnosis  by  general
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ractitioners,  otorhinolaryngologists,  dentists,  and  occupa-
ional  health  physicians.
Technological  progress  has  been  made  in  surgery  and
adiotherapy,  allowing  more  precise  treatment  of  the
umour  while  sparing  healthy  tissues.  Survival  has  been  con-
iderably  improved  over  the  last  40  years,  but  this  disease
till  has  a  poor  prognosis  due  to  poor  control  local.
Improvement  of  primary  prevention  measures  and  early
creening  will  probably  play  a  fundamental  role  in  the  future
o  reduce  the  mortality  of  these  cancers.
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